Journal of Materials Science: Materials in Medicine

, Volume 24, Issue 12, pp 2809–2817 | Cite as

Tetracycline-encapsulated P(3HB) microsphere-coated 45S5 Bioglass®-based scaffolds for bone tissue engineering

  • D. Meng
  • L. Francis
  • I. D. Thompson
  • C. Mierke
  • H. Huebner
  • A. Amtmann
  • I. Roy
  • A. R. Boccaccini
Article

Abstract

Bioglass®-based scaffolds for bone tissue engineering have been developed, which can also serve as carriers for drug delivery. For this, P(3HB) microspheres (PMSs) loaded with tetracycline were fabricated and immobilised on the scaffold surfaces by a modified slurry dipping technique. The sustained drug delivery ability in simulated body fluid was confirmed by using UV–Vis absorption spectroscopy measurements. The MTT assay using mouse fibroblast cells provided evidence that the tetracycline loaded microspheres produced in this study show limited cytotoxicity. The scaffolds developed in this work provide mechanical support, adequate 3D surface roughness, bioactivity and controlled drug delivery function, and are thus interesting candidates for bone tissue engineering applications.

References

  1. 1.
    Chen QZ, Thompson ID, Boccaccini AR. 45S5 Bioglass (R)-derived glass–ceramic scaffolds for bone tissue engineering. Biomaterials. 2006;27:2414–25.CrossRefGoogle Scholar
  2. 2.
    Bretcanu O, Misra S, Roy I, Renghini C, Fiori F, Boccaccini AR, Salih V. In vitro biocompatibility of 45S5 Bioglass (R)-derived glass–ceramic scaffolds coated with poly(3-hydroxybutyrate). J Tissue Eng Regen Med. 2009;3:139–48.CrossRefGoogle Scholar
  3. 3.
    Chen QZ, Efthymiou A, Salih V, Boccaccinil AR. Bioglass (R)-derived glass-ceramic scaffolds: study of cell proliferation and scaffold degradation in vitro. J Biomed Mater Res Part A. 2008;84A:1049–60.CrossRefGoogle Scholar
  4. 4.
    Xynos ID, Edgar AJ, Buttery LDK, Hench LL, Polak JM. Gene-expression profiling of human osteoblasts following treatment with the ionic products of Bioglass (R) 45S5 dissolution. J Biomed Mater Res. 2001;55:151–7.CrossRefGoogle Scholar
  5. 5.
    Hench LL. Genetic design of bioactive glass. J Eur Ceram Soc. 2009;29:1257–65.CrossRefGoogle Scholar
  6. 6.
    Gorustovich AA, Roether JA, Boccaccini AR. Effect of bioactive glasses on angiogenesis: a review of in vitro and in vivo evidences. Tissue Eng Part B. 2010;16:199–207.CrossRefGoogle Scholar
  7. 7.
    Hoppe A, Güldal NS, Boccaccini AR. A review of the biological response to ionic dissolution products from bioactive glasses and glass–ceramics. Biomaterials. 2011;32:2757–74.CrossRefGoogle Scholar
  8. 8.
    Soundrapandian C, Sa B, Datta S. Organic–inorganic composites for bone drug delivery. AAPS PharmSciTech. 2009;10:1158–71.CrossRefGoogle Scholar
  9. 9.
    Lee SH, Shin H. Matrices and scaffolds for delivery of bioactive molecules in bone and cartilage tissue engineering. Adv Drug Deliv Rev. 2007;59:339–59.CrossRefGoogle Scholar
  10. 10.
    Mourino V, Boccaccini AR. Bone tissue engineering therapeutics: controlled drug delivery in three-dimensional scaffolds. J R Soc Interface. 2010;7:209–27.CrossRefGoogle Scholar
  11. 11.
    Vo TN, Kasper FK, Mikos AG. Strategies for controlled delivery of growth factors and cells for bone regeneration. Adv Drug Deliv Rev. 2012;64(12):1292–309.CrossRefGoogle Scholar
  12. 12.
    Baroli B. From natural bone grafts to tissue engineering therapeutics: brainstorming on pharmaceutical formulative requirements and challenges. J Pharm Sci. 2009;98:1317–75.CrossRefGoogle Scholar
  13. 13.
    Domingues ZR, Cortes ME, Gomes TA, Diniz HF, Freitas CS, Gomes JB, Faria AMC, Sinisterra RD. Bioactive glass as a drug delivery system of tetracycline and tetracycline associated with beta cyclodextrin. Biomaterials. 2004;25:327–33.CrossRefGoogle Scholar
  14. 14.
    Kim HW, Knowles JC, Kim HE. Development of hydroxyapatite bone scaffold for controlled drug release via poly(epsilon-caprolactone) and hydroxyapatite hybrid coatings. J Biomed Mater Res. 2004;70B:240–9.CrossRefGoogle Scholar
  15. 15.
    Roohani-Esfahani S-I, Lu Z, Zreiqat H. Novel, simple and reproducible method for preparation of composite hierarchal porous structure scaffolds. Mater Lett. 2011;65:2578–81.CrossRefGoogle Scholar
  16. 16.
    Yun H, Kim S-H, Khang D, Choi J, Kim H, Kang M. Biomimetic component coating on 3D scaffolds using high bioactivity of mesoporous bioactive ceramics. Int J Nanomed. 2011;6:2521–31.CrossRefGoogle Scholar
  17. 17.
    Yunos DM, Bretcanu O, Boccaccini AR. Polymer-bioceramic composites for tissue engineering scaffolds. J Mater Sci. 2008;43:4433–42.CrossRefGoogle Scholar
  18. 18.
    Yang G, Yang X, Zhang L, Lin M, Sun X, Chen X, Gou X. Counterionic biopolymers-reinforced bioactive glass scaffolds with improved mechanical properties in wet state. Mater Lett. 2012;75:80–3.CrossRefGoogle Scholar
  19. 19.
    Francis L, Meng DC, Knowles JC, Roy I, Boccaccini AR. Multi-functional P(3HB) microsphere/45S5 Bioglass (R)-based composite scaffolds for bone tissue engineering. Acta Biomater. 2010;6:2773–86.CrossRefGoogle Scholar
  20. 20.
    Roohani-Esfahani SI, Nouri-Khorasani S, Lu ZF, Appleyard RC, Zreiqat H. Effects of bioactive glass nanoparticles on the mechanical and biological behavior of composite coated scaffolds. Acta Biomater. 2011;7:1307–18.CrossRefGoogle Scholar
  21. 21.
    Wu C, Fan W, Chang J, Xiao Y. Mussel-inspired SiO2 scaffolds with improved mineralization and cytocompatibility for drug delivery and bone tissue engineering. J Mater Chem. 2011;21:18300–7.CrossRefGoogle Scholar
  22. 22.
    Erol MM, Mouriňo V, Newby P, Chatzistavrou X, Roether JA, Hupa L, Boccaccini AR. Copper releasing boron containing bioactive glass-based scaffolds coated with alginate for bone tissue engineering. Acta Biomater. 2012;8:792–801.CrossRefGoogle Scholar
  23. 23.
    Corre Y-M, Bruzaud S, Audic J-L, Grohens Y. Morphology and functional properties of commercial polyhydroxyalkanoates: a comprehensive and comparative study. Polym Testing. 2012;31:226–35.CrossRefGoogle Scholar
  24. 24.
    Misra SK, Valappil SP, Roy I, Boccaccini AR. Polyhydroxyalkanoate (PHA)/inorganic phase composites for tissue engineering applications. Biomacromolecules. 2006;7:2249–58.CrossRefGoogle Scholar
  25. 25.
    Hayati AM, Hosseinalipour SM, Rezaie HR, Shokrgozar MA. Characterization of poly(3-hydroxybutyrate)/nano-hydroxyapatite composite scaffolds fabricated without the use of organic solvents for bone tissue engineering applications. Mater Sci Eng C. 2012;32:416–22.CrossRefGoogle Scholar
  26. 26.
    Pouton CW, Akhtar S. Biosynthetic polyhydroxyalkanoates and their potential in drug delivery. Adv Drug Deliv Rev. 1996;18:133–62.CrossRefGoogle Scholar
  27. 27.
    Foroughi MR, Karbasi S, Ebrahimi-Kahrizsangi R. Physical and mechanical properties of a poly-3-hydroxybutyrate-coated nanocrystalline hydroxyapatite scaffold for bone tissue engineering. J Porous Mater. 2012;. doi:10.1007/s10934-011-9518-1.Google Scholar
  28. 28.
    Embleton JK, Tighe BJ. Polymers for biodegradable medical devices.9. microencapsulation studies - effects of polymer composition and process parameters on poly-hydroxybutyrate hydroxyvalerate microcapsule morphology. J Microencapsul. 1992;9:73–87.CrossRefGoogle Scholar
  29. 29.
    Francis L, Meng D, Knowles J, Keshavarz T, Boccaccini AR, Roy I. Controlled delivery of gentamicin using poly(3-hydroxybutyrate) microspheres. Int J Mol Sci. 2011;12:4294–314.CrossRefGoogle Scholar
  30. 30.
    Zolnik BS, Burgess DJ. Effect of acidic pH on PLGA microsphere degradation and release. J Control Release. 2007;122:338–44.CrossRefGoogle Scholar
  31. 31.
    Valappil SP, Misra SK, Boccaccini AR, Keshavarz T, Bucke C, Roy I. Large scale production and efficient recovery of PHB with desirable material properties, from the newly characterised Bacillus cereus SPV. J Biotechnol. 2007;132:251–8.CrossRefGoogle Scholar
  32. 32.
    Meng D, Ioannou J, Boccaccini AR. Bioglass-based scaffolds with carbon nanotube coating for bone tissue engineering. J Mater Sci Mater Med. 2009;20:2139–44.CrossRefGoogle Scholar
  33. 33.
    Tanahashi M, Yao T, Kokubo T, Minoda M, Miyamato T, Nakamura T, Yamamuro T. Apatite coating on organic polymers by a biomimetic precess. J Am Ceram Soc. 1994;77:2805.CrossRefGoogle Scholar
  34. 34.
    Medvecky L, Stulajterova R, Briancin J. Study of controlled tetracycline release from porous calcium phosphate/polyhydroxybutyrate composites. Chem Pap. 2007;61:477–84.CrossRefGoogle Scholar
  35. 35.
    Ratier A, Freche M, Lacout JL, Rodriguez F. Behaviour of an injectable calcium phosphate cement with added tetracycline. Int J Pharm. 2004;274:261–8.CrossRefGoogle Scholar
  36. 36.
    Ratier A, Gibson IR, Best SM, Freche M, Lacout JL, Rodriguez F. Setting characteristics and mechanical behaviour of a calcium phosphate bone cement containing tetracycline. Biomaterials. 2001;22:897–901.CrossRefGoogle Scholar
  37. 37.
    Tongaree S, Flanagan DR, Poust RI. The interaction between oxytetracycline and divalent metal ions in aqueous and mixed solvent systems. Pharm Dev Technol. 1999;4:581–91.CrossRefGoogle Scholar
  38. 38.
    Gbureck U, Vorndran E, Muller FA, Barralet JE. Low temperature direct 3D printed bioceramics and biocomposites as drug release matrices. J Control Release. 2007;122:173–80.CrossRefGoogle Scholar
  39. 39.
    Wenke JC, Guelcher SA. Dual delivery of an antibiotic and a growth factor addresses both the microbiological and biological challenges of contaminated bone fractures. Expert Opin Drug Deliv. 2011;8:1555–69.CrossRefGoogle Scholar
  40. 40.
    Kimakhe S, Bohic S, Larosse C, Reynaud A, Pilet P, Giumelli B, Heymann D, Daculsi G. Biological activities of sustained polymixin B release from calcium phosphate biomaterial prepared by dynamic compaction: an in vitro study. J Biomed Mater Res. 1999;47:18–27.CrossRefGoogle Scholar
  41. 41.
    Vallet-Regí M, Ruiz-González L, Izquierdo-Barba I, González-Calbet J. Revisiting silica based ordered mesoporous materials: medical applications. J Mater Chem. 2006;16:26–31.CrossRefGoogle Scholar
  42. 42.
    Wu C, Miron R, Sculean A, Kaskel S, Doert T, Schulze R, Zhang Y. Proliferation, differentiation and gene expression of osteoblasts in boron-containing associated with dexamethasone deliver from mesoporous bioactive glass scaffolds. Biomaterials. 2011;32:7068–78.CrossRefGoogle Scholar
  43. 43.
    Mortera R, Onida B, Fiorilli S, Cauda V, Vitale-Brovarone C, Baino F, Verné E, Garrone E. Synthesis and characterization of MCM-41 spheres inside bioactive glass–ceramic scaffold. Chem Eng J. 2007;137:54–61.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • D. Meng
    • 1
  • L. Francis
    • 2
  • I. D. Thompson
    • 3
  • C. Mierke
    • 4
    • 7
  • H. Huebner
    • 5
  • A. Amtmann
    • 5
  • I. Roy
    • 2
  • A. R. Boccaccini
    • 1
    • 6
  1. 1.Department of MaterialsImperial College LondonLondonUK
  2. 2.Department of Molecular and Applied BiologyUniversity of WestminsterLondonUK
  3. 3.Biomaterials Unit, Dental InstituteKing’s College LondonLondonUK
  4. 4.Biophysics GroupUniversity of Erlangen-NurembergErlangenGermany
  5. 5.Institute of Bioprocess EngineeringUniversity of Erlangen-NurembergErlangenGermany
  6. 6.Institute of BiomaterialsUniversity of Erlangen-NurembergErlangenGermany
  7. 7.Soft Matter Physics Division, Faculty of Physics and Earth ScienceUniversity of LeipzigLeipzigGermany

Personalised recommendations